安科生物：签署PA3-17注射液产品独家代理框架协议

Core Viewpoint - The company has signed an exclusive agency framework agreement with Boshengji Company for the product CD7-CAR-T (PA3-17 injection) in the Greater China region, aiming for collaborative development and resource integration [1] Group 1 - The agreement was signed on November 11, 2025 [1] - The exclusive agency pertains to the product PA3-17 injection after its market launch [1] - The collaboration is intended to leverage the strengths of both parties for synergistic growth [1]